Logo image of IBRX

IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis

NASDAQ:IBRX - US45256X1037 - Common Stock

2.3137 USD
-0.06 (-2.38%)
Last: 9/4/2025, 12:09:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IBRX. IBRX was compared to 542 industry peers in the Biotechnology industry. IBRX has a bad profitability rating. Also its financial health evaluation is rather negative. IBRX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IBRX has reported negative net income.
In the past year IBRX has reported a negative cash flow from operations.
In the past 5 years IBRX always reported negative net income.
IBRX had a negative operating cash flow in each of the past 5 years.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

Looking at the Return On Assets, with a value of -91.30%, IBRX is doing worse than 73.06% of the companies in the same industry.
Industry RankSector Rank
ROA -91.3%
ROE N/A
ROIC N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

IBRX has a Gross Margin of 26.05%. This is in the better half of the industry: IBRX outperforms 72.51% of its industry peers.
The Profit Margin and Operating Margin are not available for IBRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

2

2. Health

2.1 Basic Checks

IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IBRX has more shares outstanding
Compared to 5 years ago, IBRX has more shares outstanding
Compared to 1 year ago, IBRX has a worse debt to assets ratio.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IBRX has an Altman-Z score of -12.88. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -12.88, IBRX is not doing good in the industry: 76.94% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.88
ROIC/WACCN/A
WACC10.85%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

A Current Ratio of 4.11 indicates that IBRX has no problem at all paying its short term obligations.
The Current ratio of IBRX (4.11) is comparable to the rest of the industry.
IBRX has a Quick Ratio of 3.98. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a Quick ratio (3.98) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 3.98
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

IBRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.06%, which is quite impressive.
The Revenue has grown by 4227.22% in the past year. This is a very strong growth!
Measured over the past years, IBRX shows a very strong growth in Revenue. The Revenue has been growing by 46.30% on average per year.
EPS 1Y (TTM)51.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)4227.22%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%2423.88%

3.2 Future

IBRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.55% yearly.
Based on estimates for the next years, IBRX will show a very strong growth in Revenue. The Revenue will grow by 164.88% on average per year.
EPS Next Y13.89%
EPS Next 2Y18.52%
EPS Next 3Y23.85%
EPS Next 5Y31.55%
Revenue Next Year603.46%
Revenue Next 2Y284.27%
Revenue Next 3Y233.14%
Revenue Next 5Y164.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as IBRX's earnings are expected to grow with 23.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.52%
EPS Next 3Y23.85%

More info and screens

0

5. Dividend

5.1 Amount

IBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNITYBIO INC

NASDAQ:IBRX (9/4/2025, 12:09:02 PM)

2.3137

-0.06 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners9.35%
Inst Owner Change52.08%
Ins Owners4.47%
Ins Owner Change0%
Market Cap2.19B
Analysts85.45
Price Target10.4 (349.5%)
Short Float %25.83%
Short Ratio9.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.01%
Min EPS beat(2)-14.89%
Max EPS beat(2)10.87%
EPS beat(4)3
Avg EPS beat(4)21.63%
Min EPS beat(4)-14.89%
Max EPS beat(4)55.88%
EPS beat(8)4
Avg EPS beat(8)-1.88%
EPS beat(12)5
Avg EPS beat(12)-7.19%
EPS beat(16)6
Avg EPS beat(16)-7.21%
Revenue beat(2)2
Avg Revenue beat(2)7.45%
Min Revenue beat(2)1.11%
Max Revenue beat(2)13.79%
Revenue beat(4)3
Avg Revenue beat(4)28.54%
Min Revenue beat(4)-5.28%
Max Revenue beat(4)104.56%
Revenue beat(8)6
Avg Revenue beat(8)97.31%
Revenue beat(12)10
Avg Revenue beat(12)224.67%
Revenue beat(16)13
Avg Revenue beat(16)268.51%
PT rev (1m)-10.53%
PT rev (3m)-9.33%
EPS NQ rev (1m)1.82%
EPS NQ rev (3m)-197.3%
EPS NY rev (1m)-9.11%
EPS NY rev (3m)-5.1%
Revenue NQ rev (1m)15.3%
Revenue NQ rev (3m)-13.39%
Revenue NY rev (1m)9.28%
Revenue NY rev (3m)7.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.64
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.06
BVpS-0.6
TBVpS-0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -91.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.05%
FCFM N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.58%
Cap/Sales 12.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 3.98
Altman-Z -12.88
F-Score6
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)249.59%
Cap/Depr(5y)199.51%
Cap/Sales(3y)15458.8%
Cap/Sales(5y)10051.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y13.89%
EPS Next 2Y18.52%
EPS Next 3Y23.85%
EPS Next 5Y31.55%
Revenue 1Y (TTM)4227.22%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%2423.88%
Revenue Next Year603.46%
Revenue Next 2Y284.27%
Revenue Next 3Y233.14%
Revenue Next 5Y164.88%
EBIT growth 1Y20.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.22%
OCF growth 3YN/A
OCF growth 5YN/A